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HIV-1 infection is characterized by high initial levels of plasma viremia that are variably controlled by virus-specific CD8^+^ T cell responses^[@CR5],[@CR6]^. Individuals who fail to control viremia, rapidly develop immunodeficiency. In contrast, strong, broad HIV-specific CD8^+^ and CD4^+^ T cell responses have been associated with spontaneous viral control (that is, elite controllers, viral load \<50 copies per ml) and delayed progression to AIDS^[@CR7]--[@CR9]^.

ART is highly effective in maintaining viral suppression but does not boost host antiviral immunity because it limits antigen availability. In contrast, antibodies do not prevent virus replication or production and, unlike small molecule drugs, they have dual functionality; variable domains neutralize the virus and constant domains (Fc) engage the host immune system^[@CR3]^. In humanized mice, Fc interactions lead to accelerated clearance of viruses and infected cells^[@CR10]^. bNAb administration to macaques infected with chimeric simian and human immunodeficiency viruses (SHIV) is associated with CD8^+^ T cell-dependent lasting control in a fraction of the treated animals^[@CR11]^. In humans, bNAb monotherapy was associated with increased T cell responses in 9 of 12 individuals; however this occurred after rebound viremia in all but 3 individuals^[@CR12]^. Whether bNAb therapy has a positive impact on HIV-1-specific T cell immune responses in infected humans with prolonged suppression during ART interruption has not been determined.

In a phase 1b clinical trial, individuals who were infected with HIV-1 and on ART were infused with a combination of two bNAbs, 3BNC117 and 10-1074, at 0, 3 and 6 weeks (Fig. [1a](#Fig1){ref-type="fig"})^[@CR4]^. ART was interrupted 2 d after the first antibody infusion. Nine bNAb-infused individuals harboring viruses sensitive to both bNAbs maintained viral suppression for at least 15 weeks following analytical treatment interruption (ATI) (Extended Data Fig. [1a,b](#Fig5){ref-type="fig"})^[@CR4]^.Fig. 1Increased frequency of Gag-specific T cells during ATI in bNAb-treated individuals.**a**, Study design. **b**,**c**, Net frequency of cytokine^+^ CD8^+^ (**b**) or CD4^+^ cells (**c**) after Gag stimulation at weeks −2, 6/7, 12 and 18. Total cytokine^+^ cells include cells that express at least one cytokine and effector function upon Gag stimulation (CD107A, IFN-γ, MIP1-β and/or TNF-α for CD8^+^; CD40L, IFN-γ, IL-2 and/or TNF-α for CD4^+^). Net value was calculated by subtracting the frequency of cytokine^+^ cells detected in a DMSO control. Bars show median values. Symbols represent biologically independent samples from *n* = 9 (weeks --2, 6/7 and 12) and *n* = 7 (week 18) bNAb-treated individuals with suppressed viral load during ATI (week 18 sample was not available for individual 9244 and individual 9242 reinitiated ART after viral rebound at week 15). Lines connect data from the same donor. *P* values comparing responses at week 6/7, 12 or 18 versus baseline (week --2) were calculated using a paired two-tailed Wilcoxon test.

Individuals who were infected with HIV-1 and on ART show stable or decreasing levels of HIV-1-specific CD8^+^ and CD4^+^ T cell responses over time^[@CR13]--[@CR15]^. To determine whether the combination of bNAb treatment and ATI was associated with alterations of CD8^+^ and CD4^+^ T cell responses to HIV-1, we analyzed the peripheral blood of the nine individuals on bNAb + ATI at baseline (week −2) and during bNAb-mediated suppression (weeks 6/7, 12 and 18; Extended Data Fig. [1b](#Fig5){ref-type="fig"}; week 18 samples were limited to seven individuals). Peripheral blood mononuclear cells (PBMCs) were stimulated with an HIV-1 Consensus B Gag peptide pool. CD8^+^ T cells were analyzed for expression of interferon (IFN)-γ, tumor necrosis factor (TNF)-α, macrophage inflammatory protein (MIP)1-β and the degranulation marker CD107A; CD4^+^ T cells were analyzed for expression of IFN-γ, TNF-α, interleukin (IL)-2 and CD40L (Supplementary Table [1](#MOESM1){ref-type="media"} and Supplementary Fig. [1a--c](#MOESM1){ref-type="media"}).

In line with previous reports^[@CR13]--[@CR15]^, anti-HIV-1 T cell responses in individuals on long-term viral suppression by ART alone remained stable over time (Extended Data Fig. [2a,b](#Fig6){ref-type="fig"}). In contrast, the frequency of antigen-specific CD8^+^ T cells expressing IFN-γ, TNF-α, MIP1-β and/or CD107A increased significantly in all nine individuals receiving bNAbs during ATI after 6/7 weeks (Fig. [1b](#Fig1){ref-type="fig"} and Extended Data Fig. [3a](#Fig7){ref-type="fig"}). Of note, bNAb plasma levels were highest at this time point^[@CR4]^ (Extended Data Fig. [1b](#Fig5){ref-type="fig"}). CD8^+^ T cell responses decreased by week 12 in six individuals but remained significantly elevated for IFN-γ, TNF-α and MIP1-β when compared to baseline. At week 18, when antibody levels were 2--3 orders of magnitude below the week 6/7 peak, CD8^+^ T cell responses were similar to week 12, but interpretation of these data was limited by the small sample size (Fig. [1b](#Fig1){ref-type="fig"}).

CD4^+^ T cells expressing IFN-γ, CD40L, TNF-α and/or IL-2 in response to Gag also increased significantly between baseline and week 6/7 in eight bNAb + ATI individuals (Fig. [1c](#Fig1){ref-type="fig"}). When measured individually, only CD40L and TNF-α remained significantly elevated at week 12 and no responses were significantly elevated at week 18. However, the total frequency of cytokine^+^ CD4^+^ T cells (percentage of cells positive for one or more cytokines or functional markers) was above baseline at all time points tested (Fig. [1c](#Fig1){ref-type="fig"}). In contrast, cytomegalovirus (CMV) pp65-specific T cell responses remained unchanged (Extended Data Fig. [4a,b](#Fig8){ref-type="fig"}), suggesting that the increased T cell immunity in bNAb + ATI individuals was specific to HIV-1. In summary, CD8^+^ and CD4^+^ T cell responses to Gag were most prominent at week 6/7 but remained elevated for weeks after the last antibody dose in individuals who remained suppressed while receiving bNAbs during ATI.

Two additional individuals recruited to the study harbored antibody-resistant viruses and showed early rebound after ATI (9245 and 9251, Extended Data Fig. [5a,b](#Fig9){ref-type="fig"})^[@CR4]^. Gag-specific T cell responses in both participants were analyzed at baseline, week 6/7 and week 11 or 12 after reinitiation of ART. Where the frequency of cytokine^+^ cells for CD8^+^ and CD4^+^ increased for individual 9245, the responses decreased for 9251 (Extended Data Fig. [5c](#Fig9){ref-type="fig"}), consistently with rebound viremia being sufficient to increase CD8^+^ T cell responses in some individuals^[@CR16]^.

Polyfunctional HIV-1-specific CD8^+^ T cells have been associated with enhanced HIV-1 control^[@CR9],[@CR17]^, whereas other studies reported superior antiviral functions of MIP1-β monofunctional cells^[@CR18]^. To examine Gag-specific T cells in bNAb + ATI individuals for polyfunctional responses, we performed coexpression analysis using Boolean gating. Gag-specific CD8^+^ T cells coexpressing IFN-γ, TNF-α, MIP1-β and CD107A were significantly increased at weeks 6/7 and 12 after receiving bNAb therapy (Fig. [2a](#Fig2){ref-type="fig"}). However, the greatest absolute increase in CD8^+^ T cell responses to Gag was associated with expansion of MIP1-β^+^ single-positive cells (Fig. [2a](#Fig2){ref-type="fig"}). In addition, the frequency of CD4^+^ T cells expressing IFN-γ or CD40L alone or in combination with other functions and IL-2/TNF-α-double positive cells was also increased (Fig. [2b](#Fig2){ref-type="fig"}). Thus, several subsets of Gag-specific mono- or polyfunctional CD8^+^ and CD4^+^ T cells were augmented at weeks 6/7 and 12 compared to baseline for bNAb-treated individuals (Fig. [2a,b](#Fig2){ref-type="fig"}).Fig. 2Polyfunctionality of Gag-specific T cells.T cell cytokine coexpression after HIV-1 Gag peptide pool stimulation was evaluated in bNAb + ATI individuals by ICS and analyzed using combination gates. **a**, Coexpression of CD107A, IFN-γ, MIP1-β and TNF-α in CD8^+^ T cells. **b**, Coexpression of CD40L, IFN-γ, IL-2 and TNF-α in CD4^+^ T cells. Box-and-whisker plots show median values (line), 25th to 75th percentiles (box outline) and minimum and maximum values (whiskers); *n* = 9 (weeks −2, 6/7 and 12) and *n* = 7 (week 18) biologically independent samples from bNAb-treated individuals with suppressed viral load during ATI. *P* values comparing responses at week 6/7, 12 or 18 versus baseline (week −2) were calculated using a paired two-tailed Wilcoxon test.

Activation-induced marker (AIM) assays give a broader overview of the total peptide-reactive T cell response and identify cells without cytokine expression or expressing cytokines that are challenging to detect by intracellular cytokine staining (ICS)^[@CR19],[@CR20]^. We therefore used the AIM assay as an alternative, cytokine-independent method to confirm our findings obtained by ICS. CD4^+^ or CD8^+^AIM^+^ cells were identified as CD69^+^ programmed death ligand (PD-L)1^+^ or CD69^+^4-1BB^+^ or PD-L1^+^4-1BB^+^ after Gag peptide pool stimulation (Supplementary Fig. [2](#MOESM1){ref-type="media"} and Supplementary Table [2](#MOESM1){ref-type="media"}).

Similarly to ICS, we found increased Gag-specific T cell responses in seven (CD8^+^) or six (CD4^+^) out of nine bNAb + ATI individuals at week 12 compared to baseline (Fig. [3a,b](#Fig3){ref-type="fig"}). As expected^[@CR19]^, the frequency of Gag-specific CD4^+^ and CD8^+^ T cells was higher in the AIM assay but correlated with ICS (Fig. [3c,d](#Fig3){ref-type="fig"}, *r* = 0.64). We did not detect changes in human leukocyte antigen (HLA)-DR^+^CD38^+^ or programmed cell death (PD)-1^+^ cells within AIM^+^ Gag-specific T cell responses at week 12 versus baseline (Extended Data Fig. [6](#Fig10){ref-type="fig"}).Fig. 3AIM assay evaluation of T cell responses to multiple HIV-1 antigens.AIM^+^ T cells include cells that were PD-L1^+^CD69^+^ or 4-1BB^+^CD69^+^ or PD-L1^+^4-1BB^+^. **a**, Net frequency of HIV-1 Gag-specific AIM^+^CD8^+^ (left, red) and CD4^+^ T cells (right, blue) for each bNAb + ATI individual. Net frequency of the Gag-stimulated condition was calculated by subtracting the frequency detected in a DMSO control. **b**, Comparison of net frequency HIV-1 Gag-specific AIM^+^CD8^+^ (left, blue) and CD4^+^ T cells (right, red) at week −2 and week 12. Symbols represent biologically independent samples from *n* = 9 bNAb + ATI individuals. Lines connect data from the same donor. Bars show median values. **c**, Comparison of the frequency of Gag-specific CD8^+^ or CD4^+^ T cells identified by AIM assay or ICS. The or-gate strategy was used for both assays. Symbols represent biologically independent samples from *n* = 9 bNAb + ATI individuals (samples obtained at week −2 and 12 for each individual were included for comparison). Lines connect data from the same donor and time point. **d**, Relationship between the frequency of Gag-specific CD8^+^ and CD4^+^ T cell responses identified either by AIM assay or ICS. Symbols represent biologically independent samples from *n* = 9 bNAb + ATI individuals (samples obtained at week −2 and 12 for each individual were included for comparison). Association was determined by Spearman correlation. **e**, Net frequency of HIV-1 Pol, Nef, gp120 or gp41-specific CD8^+^ (upper graphs) or CD4^+^ T cells (lower graphs) identified by AIM assay in bNAb + ATI individuals at week −2 and week 12. Symbols represent biologically independent samples from *n* = 9 bNAb + ATI individuals. Lines connect data from the same donor. Median values are shown as bars. *P* values indicated in **b**,**c**,**e** were calculated by a paired two-tailed Wilcoxon test.

We further used the AIM assay to investigate responses to less immunodominant HIV-1 antigens with expected lower frequencies than Gag. In contrast to Gag, we did not find a significant increase in HIV-1-specific T cell responses directed against HIV-1 Pol, Nef, gp120 or gp41 at the cohort level (Fig. [3e](#Fig3){ref-type="fig"}). Nevertheless, enhanced CD8^+^ and/or CD4^+^ T cell responses to these HIV-1 proteins were noted in several individuals at week 12 compared to week −2, including against gp120 and gp41 (Extended Data Fig. [7a,b](#Fig11){ref-type="fig"}). Specifically, the two individuals with controlled viremia beyond 30 weeks showed increased CD8^+^ and CD4^+^ responses to nearly all HIV-1 antigens tested at week 12 (Extended Data Fig. [7a--c](#Fig11){ref-type="fig"}, participants 9254 and 9255). This was not seen in individuals who rebounded before week 26 after ATI (Extended Data Fig. [7a--c](#Fig11){ref-type="fig"}, participants 9241, 9242, 9243, 9244, 9246, 9247 and 9252). However, the association between prolonged control and breadth in these two individuals is anecdotal. Larger studies will be required to understand the precise relationship between prolonged control, bNAb therapy and enhanced breadth of T cell immunity.

To determine whether the increased HIV-1 Gag-specific T cell responses were directed against pre-existing or new peptide epitopes, we stimulated PBMCs with a peptide library spanning the entire HIV Gag protein Consensus B sequence (Supplementary Table [3](#MOESM1){ref-type="media"}) and compared IFN-γ responses before and after ATI for the nine bNAb + ATI individuals. IFN-γ ELISpot responses were detectable for six study participants (Fig. [4a--d](#Fig4){ref-type="fig"}, Extended Data Fig. [8](#Fig12){ref-type="fig"} and Supplementary Table [4](#MOESM1){ref-type="media"}). Four individuals from these six (9244, 9246, 9252 and 9255) broadened the IFN-γ ELISpot response to Gag during ATI (Fig. [4a--d](#Fig4){ref-type="fig"} and Extended Data Fig. [8f](#Fig12){ref-type="fig"}). Overall, 41% (9 of 22) of the detectable responses in these six individuals at week 12 were directed against Gag epitopes that did not induce a detectable response at baseline (new responses: red dots and section, Fig. [4e,f](#Fig4){ref-type="fig"}). In contrast, none of the Gag responses detected at baseline were lost by week 12. Finally, several individuals with detectable responses at week 12 had IFN-γ ELISpot responses against the major homology region (peptide 69-76, Gag285-304; Fig. [4g](#Fig4){ref-type="fig"}), a highly conserved motif in the *gag* gene of all retroviruses^[@CR21]^. Thus, the increased IFN-γ responses that developed during bNAb therapy result from increased breadth and magnitude of detectable peptide-specific responses.Fig. 4Responses to HIV-1 Gag epitopes.PBMCs obtained at week −2 and 12 were evaluated for IFN-γ ELISpot responses to 123 peptides spanning the entire HIV-1 Gag protein (Consensus Clade B sequence). **a**--**d**, Plots showing PBMC IFN-γ ELISpot response calculated as spot-forming units (s.f.u.) per 10^6^ PBMCs for individuals with broadened IFN-γ ELISpot response at week 12 (dark gray bars) compared to week −2 (white bars): 9244, 9246, 9252 and 9255. **e**, PBMC IFN-γ ELISpot responses at week −2 were plotted against week 12 responses for all nine individuals in the bNAb + ATI group. White symbols represent responses that were below the limit of detection (LOD) for both time points. Responses were considered as new (red symbols) if responses were undetectable for week −2 and detectable for week 12. Responses were considered as unchanged (light gray symbols) if number of spots did not differ by more than twofold between both time points. Responses were considered as increased (blue symbols) if number of spots for week −2 were increased by more than twofold for week 12 versus week −2. **f**, Doughnut chart depicting proportion of new, increased or unchanged IFN-γ ELISpot responses within all detectable responses (*n* = 22) of the nine individuals at week 12. **g**, Summary of detectable IFN-γ ELISpot responses at week 12 for all nine bNAb study participants. The LOD of 50 s.f.u. per 10^6^ PBMCs is indicated as a dashed line in **a**--**e**.

To determine whether the increased HIV-1-specific T cell response could eliminate HIV-1-infected cells in vitro, we performed HIV-1 viral inhibition assays^[@CR22]^. CD4^+^ T cells from participants 9246 and 9252 at baseline were infected with HIV-1~BaL~ and cultured either alone or in the presence of CD8^+^ T cells isolated from the same individuals before and after ATI (Extended Data Fig. [9a](#Fig13){ref-type="fig"} and Supplementary Table [5](#MOESM1){ref-type="media"}). Participant 9252 showed increased suppression of HIV-1~BaL~ in vitro at week 12 compared to baseline (Extended Data Fig. [9b](#Fig13){ref-type="fig"}). However, 9246 was uninformative with no detectable impact on HIV-1~BaL~ outgrowth at baseline or week 12 (Extended Data Fig. [9b](#Fig13){ref-type="fig"}). Given the importance of HIV-1-specific CD8^+^ T cells in controlling viral replication, we also examined rebound viruses for mutations in HIV-1 *gag* in the seven individuals who rebounded before week 30. When compared to week −2 or 12, HIV-1 *gag* DNA from rebound plasma showed no consistent evidence for cytotoxic lymphocyte escape (Extended Data Fig. [10](#Fig14){ref-type="fig"}).

HIV-1-specific T cell responses likely play a key role in spontaneous control of HIV-1 viremia in elite controllers^[@CR7]--[@CR9]^. However, most individuals exhibit partial control of viral replication as evidenced by suppression of initial peak viremia by 1--2 orders of magnitude for prolonged periods of time before developing AIDS-defining clinical complications^[@CR23]^. ART is highly effective in further suppressing viremia but fails to enhance virus-specific immunity possibly because of decreased viral antigen availability.

In contrast, bNAb therapy in SHIV-infected rhesus macaques induces long-lasting CD8^+^ T cell-mediated viral suppression in a subset of the animals^[@CR11],[@CR24]^. Our data indicate that individuals who are infected with HIV-1, receiving bNAb therapy during ATI, show increased T cell immunity to HIV-1, including reactivity to Gag epitopes that were undetectable before bNAb administration. Specifically, we identified increased frequencies of MIP1-β-expressing CD8^+^ T cells, which have been associated with control of viremia^[@CR18]^. However, notably, the observational nature of this trial does not allow the determination of whether the observed expansion of HIV-1-specific T cell responses in bNAb-treated humans contributes to viral control.

Previous clinical trials in individuals who are infected with HIV-1, who underwent ATI in the absence of immune intervention, showed increased HIV-1-specific T cell responses that coincided with plasma viral rebound, suggesting that this boost in antiviral immunity was induced by increased viral replication^[@CR16],[@CR25]^. The increased T cell responses in individual 9245 are consistent with these observations (Extended Data Fig. [5](#Fig9){ref-type="fig"}). In contrast, our results demonstrate increased HIV-1 Gag-specific CD8^+^ and CD4^+^ T cell immunity in bNAb + ATI individuals at a time when bNAbs maintained viral suppression. At least two mechanisms could account for the association of bNAb treatment with increased T cell responses. One possibility is that ART interruption in the presence of antibodies results in production of bNAb-HIV-1 immune complexes that activate antigen-presenting dendritic cells and enhance their antigen-presenting and cross-presenting capabilities to produce a vaccinal effect^[@CR3],[@CR26]^. A second nonexclusive possibility is that the augmented CD8^+^ T cell response is driven by increased low-grade viral replication and antigen availability in tissues that we have not been able to assay during overt viremia suppression by bNAbs. While the underlying mechanism of the observed increased T cell immunity remains to be determined, a potentially important advantage of bNAb + ATI treatment compared to ATI alone, standard ART or T cell vaccination is that the immune system is stimulated with the individual's own virus while circulating viremia is suppressed. Whether the same effects will be seen in individuals who receive bNAbs during ART and whether the increased T cell responses are sufficient to help control infection remains to be determined.

Methods {#Sec2}
=======

All information regarding material and methods can be found in the Life Sciences [Reporting Summary](#Sec10){ref-type="sec"}.

Study design and participants {#Sec3}
-----------------------------

BNAb study participants were enrolled in an open-label phase 1b clinical trial at the Rockefeller University and University of Cologne and received three infusions with a combination of two bNAbs, 3BNC117 and 10-1074. ART was interrupted at day 2 after the first antibody infusion^[@CR4]^ (ClinicalTrials.gov identifier: NCT02825797). Viral load was assessed every 1--2 weeks and ART was reinitiated when two consecutive measurements showed viral load of \>200 copies per ml. All individuals were infected with clade B HIV-1 (ref. ^[@CR4]^). Clinical data of all participants are shown in Extended Data Figs. [1a](#Fig5){ref-type="fig"} and [5a](#Fig9){ref-type="fig"}. Individuals on continuous ART were enrolled in an observational study at the Rockefeller University. Clinical data of all ART individuals are shown in Extended Data Fig. [2a](#Fig6){ref-type="fig"}. The studies were approved by the Rockefeller University and the University of Cologne Institutional Review Boards and written informed consent was obtained from all participants before study enrollment. Secondary use of samples was approved by the University of Montréal Hospital Institutional Review Board.

Intracellular cytokine staining {#Sec4}
-------------------------------

PBMCs were thawed and rested for 2 h in RPMI 1640 medium (Gibco by Life Technologies) supplemented with 10% FBS (Seradigm), penicillin and streptomycin (Gibco by Life Technologies) and HEPES (Gibco by Life Technologies) and stimulated with a HIV-1 Consensus B Gag peptide pool (0.5 μg ml^−1^ per peptide; NIH AIDS Reagent Program) or CMV pp65 peptide pool (0.5 μg ml^−1^ per peptide; JPT Peptide Technologies) for 6 h in the presence of anti-CD107A-BV786 (BD Biosciences), Brefeldin A (BD Biosciences) and monensin (BD Biosciences) at 37 °C and 5% CO~2~. DMSO-treated cells served as a negative control. Cells were stained for aquavivid viability marker (Life Technologies) for 20 min at 4 °C and surface markers (30 min, 4 °C), followed by intracellular detection of cytokines using the IC Fixation/Permeabilization kit (eBioscience) according to the manufacturer's protocol before acquisition at an LSRFortessa flow cytometer (BD Biosciences) (see Supplementary Table [1](#MOESM1){ref-type="media"} for antibody staining panel).

Activation-induced marker assay {#Sec5}
-------------------------------

PBMCs were thawed, washed and cultured in 24-well plates at a concentration of 10 × 10^6^ cells per ml in RPMI 1640 supplemented with HEPES, penicillin and streptomycin and 10% human serum (Sigma). Cells were rested for 3 h and stimulated with 0.5 μg ml^−1^ per peptide of HIV-1 Consensus B peptide pools spanning the entire protein for Gag, Nef, Pol, gp120 or gp41 (NIH AIDS Reagent Program) for 18 h at 37 °C and 5% CO~2~. Pools for gp120 and gp41 were obtained by combining single Env peptides 1--123 (gp120) and 124--211 (gp41) (HIV-1 Consensus B Env Peptide Set). A DMSO-treated condition served as a negative control. Cells were stained for viability dye (aquavivid, Life Technologies) and surface markers (30 min, 4 °C) and cells were fixed using 2% paraformaldehyde before acquisition at a LSRII flow cytometer (BD Biosciences) (see Supplementary Table [2](#MOESM1){ref-type="media"} for antibody staining panel). DMSO-treated cells served as negative controls and were used together with fluorescence minus one controls to set gates for analysis.

IFN-γ ELISpot {#Sec6}
-------------

HIV Gag-specific IFN-γ responses were measured using an IFN-γ ELISpot assay as previously described^[@CR27]^. The 96-well hydrophobic polyvinylidene difluoride membrane-backed plates (Millipore) were pre-wetted with 35% ethanol for 45 s, washed with PBS and coated overnight at 4 °C with anti-IFN-γ capture antibody (3 μg ml^−1^ in PBS, clone NIB42, BD Biosciences). PBMCs were thawed, rested for 2 h and seeded into plates at 1--2 × 10^5^ PBMCs per well in RPMI with 10% FBS supplemented with HEPES and penicillin and streptomycin. Cells were stimulated with 123 peptides spanning the entire HIV-1 Consensus B Gag protein (10 μg ml^−1^, NIH AIDS Reagent Program; see Supplementary Table [3](#MOESM1){ref-type="media"} for all sequences) for 20 h at 37 °C and 5% CO~2~. Plates were washed with PBS-T (PBS and 0.05% Tween-20) and incubated with biotinylated anti-IFN-γ antibody (0.5 μg ml^−1^ in PBS and 0.5% BSA, clone 4S.B3; BD Biosciences) for 2 h at room temperature. Plates were washed with PBS-T and incubated with streptavidin-alkaline-phosphatase conjugate (Bio-Rad Laboratories) (1:1,000 dilution in PBS and 0.5% BSA) for 1 h at room temperature. Spots were developed using an alkaline phosphatase conjugate substrate kit (Bio-Rad Laboratories) for 4 min and the reaction was stopped with tap water. Spots were counted using an Immunospot Analyzer Instrument (Cellular Technology). PBMCs incubated with medium alone served as negative controls and staphylococcal enterotoxin B-stimulated PBMCs (0.5 μg ml^−1^) as a positive control. The s.f.u. were calculated as number of spots in test wells minus the mean number of spots in medium control wells and normalized to s.f.u. per 10^6^ PBMCs. A response was considered positive if greater than 50 s.f.u. per 10^6^ PBMCs. Week −2 and week 12 samples from the same individual were assayed together in the same experiment.

In vitro viral inhibition assay {#Sec7}
-------------------------------

The capacity of CD8^+^ T cells to suppress HIV-1 infection of autologous CD4^+^ T cells was evaluated using a previously described HIV-1 suppression assay^[@CR22]^ with minor modifications. CD4^+^ T cells were isolated using negative magnetic bead selection (StemCell Technologies) from PBMCs, rested for 2 h and cultured in RPMI and 10% FBS supplemented with PHA-L (2 μg ml^−1^; Sigma-Aldrich) and IL-2 (100 U ml^−1^; StemCell Technologies) for 72 h. After 72 h, CD8^+^ T cells were isolated from PBMCs using negative magnetic bead selection (StemCell Technologies), counted and rested for 2 h at 37 °C. Meanwhile, cultured CD4^+^ T cells were washed, counted and plated in U-bottom 96-well plates for infection with HIV-1~BaL~ (NIH AIDS Reagent Program) using a multiplicity of infection of 0.015: plates were first centrifuged at 1,200*g* for 1 h at 22 °C and then incubated for an additional hour at 37 °C. After infection, CD4^+^ T cells from different wells were pooled, washed three times and plated in U-bottom 96-well plates (50,000 cells per well) with CD8^+^ T cells at a 1:1 ratio in RPMI with 10% FBS supplemented with IL-2 (100 U ml^−1^). Uninfected CD4^+^ T cells were included as negative controls and infected CD4^+^ T cells cultured without CD8^+^ T cells served as 100% infectivity controls. At days 3, 5 and 7 after infection, cells were stained with a viability dye (aquavivid, Life Technologies) and surface markers (30 min, 4 °C), followed by intracellular detection of HIV-1 Gag (Beckman Coulter) using the IC Fixation/Permeabilization kit (eBioscience) according to the manufacturer's protocol (see Supplementary Table [5](#MOESM1){ref-type="media"} for the antibody staining panel). All experiments were performed in duplicate or triplicate, depending on cell availability.

Sequencing and phylogenetic analysis {#Sec8}
------------------------------------

*Gag* sequences from latent reservoir viruses were obtained from CD4^+^ T cell genomic DNA by near-full length HIV-1 sequencing as previously described^[@CR28]^. *Gag* sequences from rebound plasma were obtained by HIV-1 RNA extraction and single-genome amplification as previously described^[@CR29]^. In brief, HIV-1 RNA was extracted from plasma samples using the MinElute Virus Spin kit (Qiagen) followed by first-strand cDNA synthesis using SuperScript III reverse transcriptase (Invitrogen). The cDNA synthesis for plasma-derived HIV-1 RNA was performed using the antisense primer B5R2 5′-CAATCATCACCTGCCATCTGTTTTCCATA-3′. *Gag* was then amplified using the primer Gag5out 5′-TTGACTAGCGGAGGCTAGAAGG-3′ and Gag3out 5′-GATAAAACCTCCAATTCCCCCTATC-3′ in the first round and in the second round with nested primers Gag5in 5′-GAGAGATGGGTGCGAGAGCGTC-3′ and Gag3in 5′-CTGCTCCTGTATCTAATAGAGC-3′. PCRs were performed using High Fidelity Platinum Taq (Invitrogen) and run at 94 °C for 2 min; 35 cycles of 94 °C for 15 s, 58 °C for 30 s and 68 °C for 3 min; and 68 °C for 15 min. Second-round PCR was performed with 1 μl of the PCR product from the first round as a template and High Fidelity Platinum Taq at 94 °C for 2 min; 45 cycles of 94 °C for 15 s, 58 °C for 30 s and 68 °C for 3 min; and 68 °C for 15 min.

Amino acid alignments of intact *gag* sequences were obtained by using ClustalW v.2.1 (ref. ^[@CR30]^) under the BLOSUM cost matrix. Sequences with premature stop codons were excluded from all analyses. Maximum likelihood phylogenetic trees were then generated from these alignments using RAxML v.8.2.9 (ref. ^[@CR31]^) under the GTRGAMMA model with 1,000 bootstraps. To analyze changes between reservoir and rebound viruses, *gag* sequences were aligned at the amino-acid-level to a HXB2 reference using ClustalW v.2.1.

Data analysis {#Sec9}
-------------

Flow cytometric data were analyzed using FlowJo v.10.5.0 for Mac. Statistical analyses were performed using GraphPad Prism v.8.0.1 for Mac using nonparametric tests. Pairwise comparisons were performed using the two-sided Wilcoxon matched-pairs signed rank test.

Reporting Summary {#Sec10}
-----------------

Further information on research design is available in the [Nature Research Reporting Summary](#MOESM2){ref-type="media"} linked to this article.

Online content {#Sec11}
==============

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at 10.1038/s41591-019-0747-1.
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Supplementary InformationSupplementary Figs. 1 and 2 and Supplementary Tables 1--5. Reporting Summary

Extended data {#Sec12}
=============

Extended Data Fig. 1Study participant clinical characteristics.(**a**) Study participant demographics and baseline clinical data^[@CR4]^. Amer Indian: American Indian; Hisp: Hispanic; cobi: cobicistat; DTG: dolutegravir; EFV: efavirenz; EVG: elvitegravir; FTC: emtricitabine; RPV: rilpivirine; TAF: tenofovir alafenamide fumarate; TDF: tenofovir disoproxil fumarate. NNRTI-based regimens were switched four weeks before ART interruption due to longer half-lives of NNRTIs. All participants harboured clade B viruses. Viral load \<20D: plasma HIV-1 RNA detected but not quantifiable by clinical assays. d0: day 0; dx: diagnosis; Scr: screening. (**b**) Levels of plasma HIV-1 RNA (black; left y axis) and serum concentration of 3BNC117 (red) and 10-1074 (blue, right y axis) in the 9 participants enrolled in the bNAb+ATI trial^[@CR4]^.

Extended Data Fig. 2Frequency of Gag-specific CD4^+^ and CD8^+^ unchanged in ART-treated individuals over time.T cell cytokine coexpression after 6h HIV-1 Gag peptide pool stimulation was evaluated by intracellular cytokine staining (ICS) in individuals on continuous ART. (**a**) Demographics and clinical data of ART-treated individuals. 3TC: lamivudine; ABC: abacavir; cobi: cobicistat; DRV: darunavir; DTG: dolutegravir; EFV: efavirenz; EVG: elvitegravir; FTC: emtricitabine; RAL: raltegravir; rit: ritonavir; RPV: rilpivirine; SQV: saquinavir; TAF: tenofovir alafenamide fumarate; TDF: tenofovir disoproxil fumarate. Viral load \<20D: plasma HIV-1 RNA detected but not quantifiable by clinical assays. n.d.: not determined. (**b**) Cytokine analysis of CD8^+^ and CD4^+^ after HIV-1 Gag peptide pool stimulation at week 0 and 12. Symbols represent biologically independent samples from n=13 individuals on continuous ART. Lines connect data from the same donor. Bars show median values. P values were calculated by paired two-tailed Wilcoxon test.

Extended Data Fig. 3Individual Gag-specific T cell responses measured by ICS.(**ab**) Net frequency of total cytokine^+^ CD8^+^ (**a**) or CD4^+^ cells (**b**) after Gag stimulation for each individual study participant. Total cytokine^+^ cells include cells that express at least one cytokine/effector function upon Gag stimulation (CD107A, IFNγ, MIP1β and/or TNFα for CD8^+^; CD40L, IFNγ, IL-2 and/or TNFα for CD4^+^). Net value was calculated by subtracting frequency of total cytokine^+^ cells detected in a DMSO control. ND: Week 18 sample was not available for individual 9244. \*9242 week 18 on ART after viral rebound at week 15.

Extended Data Fig. 4Unchanged frequency of CMV-specific effector T cells detected by intracellular cytokine staining.PBMCs were stimulated with CMV pp65 peptide pools for 6h and cytokine production was evaluated by ICS in bNAb+ATI individuals at week -2 and week 12. (**ab**) Cytokine analysis of CD8^+^ (**a**) or CD4^+^ T cells (**b**) at week -2 and week 12 after CMV pp65 stimulation. Net frequency of stimulated condition was calculated by subtracting frequency detected in a DMSO control. Symbols represent biologically independent samples from n=9 bNAb+ATI individuals. Lines connect data from the same donor. Bars show median values. P values are indicated in graphs and were calculated by paired two-tailed Wilcoxon test.

Extended Data Fig. 5HIV-1 Gag-specific T cell responses in early rebounders with bNAb-resistant reservoir.(**a**) Study participant demographics and baseline clinical data^[@CR4]^. Hisp: Hispanic; cobi: cobicistat; EVG: elvitegravir; FTC: emtricitabine; TAF: tenofovir alafenamide fumarate; TDF: tenofovir disoproxil fumarate. All participants harboured clade B viruses. d0: day 0; dx: diagnosis; Scr: screening. (**b**) Levels of plasma HIV-1 RNA (black; left y axis) and serum concentration of 3BNC117 (red) and 10-1074 (blue, right y axis) in the 2 participants enrolled in the bNAb+ATI trial with early rebound due to bNAb-resistant reservoir^[@CR4]^. (**c**) Net frequency of total cytokine^+^ CD8^+^ or CD4^+^ T cells after HIV-1 Gag stimulation in both individuals at weeks -2, 7 and 11 (9245), or weeks -2, 6 and 12 (9251).

Extended Data Fig. 6No change in HLA-DR/CD38 and PD-1 expression of HIV-1-specific T cell responses.HIV-1-specific T cell responses identified by PD-L1/CD69/4-1BB AIM assay were analyzed for surface expression of HLA-DR/CD38 and PD-1. (**a**) Representative plot showing expression of HLA-DR/CD38 and PD-1 on AIM^+^ HIV-1-specific CD8^+^ (upper graphs) and CD4^+^ T cells (lower graphs). Flow panels are representative of n=6 (CD8^+^) or n=8 (CD4^+^) biologically independent bNAb+ATI individuals. (**b**) Frequency of HLA-DR^+^CD38^+^ or PD-1^+^ of HIV-1-specific CD8^+^ and CD4^+^ T cell responses at week -2 or week 12. Symbols represent biologically independent samples from n=6 (CD8^+^) and n=8 (CD4^+^) bNAb+ATI individuals. Only samples with AIM-responses that are at least 2-fold over DMSO-stimulated control condition were analyzed for phenotype to limit the contribution of background events. Lines connect data from the same donor. Bars show median values. P values are indicated in graphs and were calculated by paired two-tailed Wilcoxon test.

Extended Data Fig. 7Dynamics of T cell responses to multiple HIV-1 antigens in bNAb+ATI individuals.(**ab**) Frequency of CD8^+^ (**a**) and CD4^+^ T cells (**b**) specific to HIV-1 Pol, Nef, gp120 or gp41 were evaluated by CD69/PD-L1/4-1BB AIM assay at weeks -2 and 12. Individuals with viral suppression \>30 weeks (9254, 9255) are marked with an asterisk (\*). (**c**) Number of increased HIV-specific CD4^+^ and CD8^+^ T cell responses in n=7 biologically independent individuals with 15-26 weeks of viral control after ATI (15-26 weeks: 9241, 9242, 9243, 9244, 9246, 9247, 9252) versus n=2 biologically independent individuals with viral control beyond 30 weeks after ATI (\>30 weeks: 9254 and 9255). Number of increased HIV-specific T cell responses was calculated as the sum of single HIV antigens (Gag, Pol, Nef, gp120, gp41) for which we observed an increase at week 12 versus week -2. Bars represent median values with IQR.

Extended Data Fig. 8PBMC IFNγ ELISpot responses were undetectable/not changed in 5 individuals.PBMCs were evaluated for IFNγ ELISpot responses to 123 HIV-1 Gag peptides spanning the entire Gag protein. Spot forming units (SFU) were calculated as number of spots in test wells subtracted by mean number of spots in media control wells and normalized to SFU/10^6^ PBMCs. A response was considered positive if greater than 50 SFU/10^6^ PBMCs (=limit of detection, LOD, dashed line). (**a-e**) Graph representing IFNγ ELISpot responses for individuals with either undetectable (9242 (**b**), 9243 (**c**), 9254 (**e**)) or unchanged response (9241 (**a**), 9247 (**d**)) at week -2 (left axis, white bars) and week 12 (right axis, gray bars). (**f**) Number of responses above LOD for n=9 biologically independent bNAb+ATI individuals at week -2 and week 12. Lines connect data from the same donors, bars represent median values. P value was calculated by paired two-tailed Wilcoxon test.

Extended Data Fig. 9*In vitro* HIV-1 inhibition assay for individuals 9252 and 9246.PHA-activated CD4^+^ T cells were infected *in vitro* with HIV-1~BaL~, cultured alone or in presence with autologous CD8^+^ T cells for 3, 5 and 7 days, and analyzed for infection using flow cytometry. (**a**) Example plot showing the frequency of infected CD4^+^ T cells (HIV-1 Gag^+^ cells with down-regulated surface CD4) for bNAb+ATI individual 9252. Flow panels are representative of n=3 technical replicates. (**b**) Fraction of residual HIV-1 Gag^+^CD4^-^ T cells after 3, 5 or 7 days of co-culture with CD8^+^ T cells obtained at week -2 or week 12 for n=2 biologically independent individuals (9252 and 9246) normalized to infected CD4^+^ T cells cultured without CD8^+^ T cells. (**c**) Fraction of residual HIV-1 Gag^+^CD4^-^ T cells after 3, 5 or 7 days of co-culture with autologous CD8^+^ T cells for one HIV-1-uninfected control individual. Each condition was done in technical duplicates or triplicates depending on cell availability and mean values are shown.

Extended Data Fig. 10Comparison of the circulating latent reservoir and rebound viruses.Maximum likelihood phylogenetic trees of full-length *gag* sequences isolated from CD4^+^ T cell genomic near-full length (NFL) HIV-1 sequencing and rebound plasma SGA from participants 9241, 9242, 9243, 9244, 9246, 9247 and 9252. Open and closed black rectangles indicate NFL-derived viruses from pre-infusion (week -2) and week 12, respectively. Viruses obtained at the time of rebound are indicated by red rectangles (plasma SGA). Asterisks indicate individuals where there is at least one identical match between a *gag* sequence from the latent reservoir and the rebound viruses.
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